Document is current
Any future updates will be listed below
-
Authors
Garlatti, Valentina
Consonni, Francesca Maria
Ballerini, Giulia
Incerti, Martina
Balboni, Andrea
Cassatella, Marco
Sica, Antonio
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01386632 at ClinicalTrials.govnct05120284 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct00096707 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct00633087 at ClinicalTrials.govDocuments that mention this clinical trial
Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma
https://doi.org/10.1136/bmjopen-2023-073839
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct00522652 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct01791595 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct03291938 at ClinicalTrials.govDocuments that mention this clinical trial
MCT4 blockade increases the efficacy of immune checkpoint blockade
https://doi.org/10.1136/jitc-2023-007349
Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies
https://doi.org/10.1136/jitc-2022-006287
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct02882321 at ClinicalTrials.govDocuments that mention this clinical trial
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity
https://doi.org/10.1136/jitc-2019-000289
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct04471415 at ClinicalTrials.govDocuments that mention this clinical trial
Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity
https://doi.org/10.1136/jitc-2019-000289
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct03428217 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct03163667 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct02903914 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct03910530 at ClinicalTrials.govDocuments that mention this clinical trial
Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
https://doi.org/10.1136/jitc-2024-010094
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours
https://doi.org/10.1136/bmjonc-2023-000249
Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
https://doi.org/10.1136/jitc-2020-001356
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct03837509 at ClinicalTrials.govDocuments that mention this clinical trial
Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
https://doi.org/10.1136/jitc-2024-010094
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct03361228 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct03254732 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct02752074 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct02752074 at ClinicalTrials.govDocuments that mention this clinical trial
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
https://doi.org/10.1136/jitc-2020-sitc2020.0028
Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy
https://doi.org/10.1136/jitc-2021-002616
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
https://doi.org/10.1136/jitc-2020-000605
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
https://doi.org/10.1136/jitc-2023-006755
nct04069026 at ClinicalTrials.govDocuments that mention this clinical trial
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
https://doi.org/10.1136/jitc-2020-sitc2020.0028
Off-tumor IDO1 target engagements determine the cancer-immune set point and predict the immunotherapeutic efficacy
https://doi.org/10.1136/jitc-2021-002616
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
https://doi.org/10.1136/jitc-2020-000605
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
https://doi.org/10.1136/jitc-2023-006755
nct04999202 at ClinicalTrials.govDocuments that mention this clinical trial
1200 Artificial intelligence image models optimizing tumor vs immune cell profiling for accurate biomarker analysis in NSCLC precision drug development
https://doi.org/10.1136/jitc-2024-sitc2024.1200
Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.2502
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
1276 Leveraging artificial intelligence (AI) models delineating tumor vs immune cell expression for scalable biomarker analysis of clinical trial samples: a digital image analysis approach for NSCLC
https://doi.org/10.1136/jitc-2023-sitc2023.1276
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy
https://doi.org/10.1136/jitc-2023-007495
nct02640534 at ClinicalTrials.govDocuments that mention this clinical trial
1200 Artificial intelligence image models optimizing tumor vs immune cell profiling for accurate biomarker analysis in NSCLC precision drug development
https://doi.org/10.1136/jitc-2024-sitc2024.1200
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct02019979 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct01310231 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct02312661 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct03800602 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct04114136 at ClinicalTrials.govDocuments that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
https://doi.org/10.1136/jitc-2023-007235
nct03874000 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
https://doi.org/10.1136/jitc-2020-002088
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct03311308 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
nct02922764 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
Documents that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
-
Funding
Funding for this research was provided by:
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN/20227YR8AW)
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN/2022T3ZALK)
Associazione Italiana per la Ricerca sul Cancro (5X1000/22757)
Associazione Italiana per la Ricerca sul Cancro (IG/27613)
Associazione Italiana per la Ricerca sul Cancro (IG/29348)
Associazione Italiana per la Ricerca sul Cancro (ITALY POST-DOC FELLOWSHIP/28263)
Fondazione Cariplo (2017BA9LM5_001)
- License Information
